Semax

Semax (also known as ACTH(4-7)-PGP) is a prominently researched experimental compound classified strictly within the Cognitive Peptide framework. Operating primarily through advanced pharmacological pathways, it functions by bDNF upregulation, nootropic effects. Enhances neural plasticity, protects neurons from oxidative stress, and improves cerebral blood circulation. with a documented biological half-life of roughly 0.33 hours, in preclinical investigative trials and independent academic studies, researchers utilizing Semax have documented significant, quantifiable biological outcomes, primarily focusing on mental clarity, focus, neuroprotection. Typical research protocols investigate administering 300 to 300mcg via nasal pathways 7x/wk. However, it is critically important to understand that while Semax demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.